Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Eric Bantz

Allergy Medford, NJ Medical Doctor

NPI 1124172598 CMS profile 1220958

103 Old Marlton Pike Ste 211, Medford, NJ 08055

Open in the dashboard

General payments

$8,211

502 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Eric Bantz of Medford, NJ is reported in the CMS Open Payments database as having received $8,211 across 502 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Allergy profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $2,077 127
2021 General $1,958 124
2020 General $1,907 133
2019 General $2,269 118

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Bantz
  • Allergy median
  • Middle half of Allergy
  • National median

In program year 2025, general payments to Eric Bantz were reported at $0. Among 526 Allergy profiles paid that year, the median was $1,143 and the middle half received between $226 and $2,504.

Show as a table
Year Eric Bantz Allergy median Middle half National median
2019 $2,269 $506 $151–$1,337 $163
2020 $1,907 $409 $108–$1,162 $114
2021 $1,958 $549 $125–$1,485 $132
2022 $2,077 $666 $161–$1,594 $149
2023 $0 $780 $186–$1,916 $160
2024 $0 $1,031 $271–$2,196 $164
2025 $0 $1,143 $226–$2,504 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. AstraZeneca Pharmaceuticals LP $1,649 94 payments
  2. GlaxoSmithKline, LLC. $844 70 payments
  3. Genzyme Corporation $609 28 payments
  4. CSL Behring $474 32 payments
  5. Regeneron Healthcare Solutions, Inc. $467 20 payments
  6. kaleo, Inc. $412 29 payments
  7. Pfizer Inc. $364 27 payments
  8. Novartis Pharmaceuticals Corporation $341 23 payments
  9. Grifols USA, LLC $335 26 payments
  10. AbbVie, Inc. $316 12 payments
  11. Other $2,401 141 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $8,211 502 payments
Products named General payments · program years 2019–2022
  1. FASENRA $560 20 payments
  2. DUPIXENT Inflammation And Immunology $467 20 payments
  3. DUPIXENT Immunology $455 30 payments
  4. SYMBICORT $452 32 payments
  5. AUVI-Q $412 29 payments
  6. RINVOQ $395 19 payments
  7. DUPIXENT Immunology $385 14 payments
  8. XOLAIR $344 23 payments
  9. NUCALA $328 16 payments
  10. Xhance $294 13 payments
  11. Other $5,565 377 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

502 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record